NEUROCRINE BIOSCIENCES INC

For the period ended Mar 31, 2026. Filed May 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 5, 2026

NBIX$169.14+0.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Income and Comprehensive Income

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

AND COMPREHENSIVE INCOME

	Three Months EndedMarch 31,
(in millions, except per share data)	2026	2025
Revenues:
Net product sales	$811.0	$563.7
Collaboration revenues	3.5	8.9
Total revenues	814.5	572.6
Operating expenses:
Cost of revenues	13.8	9.2
Research and development	296.2	263.2
Acquired in-process research and development	21.2	0.1
Selling, general, and administrative	318.5	276.5
Gain on sale of business, net of transaction costs	(28.6)	—
Total operating expenses	621.1	549.0
Operating income	193.4	23.6
Other income (expense):
Unrealized gain (loss) on equity investments	25.3	(30.6)
Investment income and other, net	28.1	21.7
Total other income (expense), net	53.4	(8.9)
Income before provision for income taxes	246.8	14.7
Provision for income taxes	48.9	6.8
Net income	$197.9	$7.9
Foreign currency translation adjustments, net of tax	—	1.5
Unrealized (loss) gain on available-for-sale debt securities, net of tax	(12.7)	1.7
Comprehensive income	$185.2	$11.1
Earnings per share:
Basic	$1.97	$0.08
Diluted	$1.91	$0.08
Weighted-average shares outstanding:
Basic	100.5	99.7
Diluted	103.4	102.5

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.